Novartis Petitions Patent Board Over Compositions Used In Gene Therapy
ALEXANDRIA, Va. — A Genzyme Corp. patent directed to compositions for improving the storage stability of recombinant virus particles for use in gene therapy should be canceled as obvious to a...To view the full article, register now.
Already a subscriber? Click here to view full article